UBS Group’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.07M | Sell |
160,576
-21,949
| -12% | -$694K | ﹤0.01% | 3044 |
|
|
2025
Q1 | $6.06M | Sell |
182,525
-52,743
| -22% | -$1.75M | ﹤0.01% | 2809 |
|
|
2024
Q4 | $8.1M | Buy |
235,268
+139,375
| +145% | +$4.8M | ﹤0.01% | 2548 |
|
|
2024
Q3 | $3.84M | Buy |
95,893
+40,593
| +73% | +$1.62M | ﹤0.01% | 2507 |
|
|
2024
Q2 | $1.67M | Sell |
55,300
-58,177
| -51% | -$1.76M | ﹤0.01% | 3004 |
|
|
2024
Q1 | $3.81M | Buy |
113,477
+69,189
| +156% | +$2.32M | ﹤0.01% | 2431 |
|
|
2023
Q4 | $1.43M | Buy |
44,288
+28,965
| +189% | +$936K | ﹤0.01% | 3150 |
|
|
2023
Q3 | $502K | Sell |
15,323
-44,174
| -74% | -$1.45M | ﹤0.01% | 3599 |
|
|
2023
Q2 | $2.09M | Buy |
59,497
+39,503
| +198% | +$1.39M | ﹤0.01% | 2649 |
|
|
2023
Q1 | $653K | Buy |
19,994
+11,227
| +128% | +$367K | ﹤0.01% | 3516 |
|
|
2022
Q4 | $483K | Buy |
8,767
+8,401
| +2,295% | +$463K | ﹤0.01% | 3730 |
|
|
2022
Q3 | $16K | Sell |
366
-995
| -73% | -$43.5K | ﹤0.01% | 6590 |
|
|
2022
Q2 | $66K | Sell |
1,361
-9,470
| -87% | -$459K | ﹤0.01% | 4718 |
|
|
2022
Q1 | $527K | Sell |
10,831
-12,275
| -53% | -$597K | ﹤0.01% | 3720 |
|
|
2021
Q4 | $986K | Buy |
23,106
+4,968
| +27% | +$212K | ﹤0.01% | 3456 |
|
|
2021
Q3 | $695K | Sell |
18,138
-9,500
| -34% | -$364K | ﹤0.01% | 3514 |
|
|
2021
Q2 | $781K | Buy |
27,638
+20,496
| +287% | +$579K | ﹤0.01% | 3439 |
|
|
2021
Q1 | $236K | Sell |
7,142
-5,769
| -45% | -$191K | ﹤0.01% | 4400 |
|
|
2020
Q4 | $467K | Sell |
12,911
-9,089
| -41% | -$329K | ﹤0.01% | 3730 |
|
|
2020
Q3 | $746K | Buy |
+22,000
| New | +$746K | ﹤0.01% | 3110 |
|